Eltrombopag per il trattamento della porpora trombocitopenica immune o idiopatica cronica
- 13 Downloads
Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura—a NICE single technology appraisal
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of eltrombopag (GlaxoSmithKline) to submit evidence for the clinical and cost effectiveness of this drug for the treatment of patients with chronic immune or idiopathic thrombocytopenic purpura (ITP), as part of the their Single Technology Appraisal (STA) process. The Aberdeen Technology Assessment Review (TAR) Group, commissioned to act as the evidence review group (ERG), critically reviewed and supplemented the submitted evidence. This paper describes the company submission, the ERG review and NICE’s subsequent decisions.
The ERG critically appraised the clinical and cost-effectiveness evidence submitted by the manufacturer, independently searched for relevant literature, conducted a critical appraisal of the submitted economic models and explored the impact of altering some of the key model assumptions as well as combining relevant sensitivity analyses.
Three trials were used to inform the safety and efficacy aspects of this submission; however, one high-quality randomized controlled trial (RAISE study) was the principal source of evidence and was used to inform the economic model. Eltrombopag had greater odds of achieving the primary outcome of a platelet count between 50×109/L and 400×109/L during the 6-month treatment period than placebo (odds ratio [OR] 8.2, 99% CI 3.6, 18.7). In the eltrombopag group, 50/83 (60%) of non-splenectomized patients and 18/49 (37%) of splenectomized patients achieved this outcome. The median duration of response was 10.9 weeks for eltrombopag (splenectomized 6 and non-splenectomized 13.4) compared with 0 for placebo. Eltrombopag patients required less rescue medication and had lower odds of bleeding events for both the splenectomized and the non-splenectomized patients.
For a watch-and-rescue strategy of care, the comparator was placebo and the ERG found that substantial reductions in the cost of eltrombopag are needed before the incremental cost per QALY is less than £30 000. There was significant uncertainty, with the incremental cost-effectiveness ratio (ICER) reported varying from £33 561 to £103 500 per QALY (splenectomized) and £39 657 to £150 245 per QALY (non-splenectomized). All costs are presented in £, year 2008 values, as this was the costing year for the manufacturer’s model. Other than bleeding, no adverse events were modelled. In relation to the long-term treatment model, the ERG questioned the robustness of the use of non-randomized non-comparative data. The base-case results restricting the time horizon to 2 years and prescribing eltrombopag as second-line treatment post-rituximab were found to be favourable towards eltrombopag. As rituximab is not a licensed treatment for ITP, the ERG were concerned that its inclusion may not be reflective of clinical practice. None of the treatment sequences resulted in an ICER approaching the recommended threshold of £30 000 per QALY gained.
Eltrombopag appears to be a safe treatment for ITP (although longterm follow-up studies are awaited) and has short-term efficacy. However, NICE found based on the evidence submitted and reviewed that there was no robust evidence on the long-term efficacy or cost effectiveness of eltrombopag and a lack of direct evidence for eltrombopag tested against other relevant comparators.
Questo progetto è stato finanziato dal National Institute for Health Research Health Technology Assessment Programme (progetto numero 08/81/01) e sarà pubblicato come parte di un compendio di articoli sull’attività degli ERG nella rivista Health Technology Assessment. Per ulteriori informazioni sul progetto si veda il sito del programma HTA (http://www.hta.ac.uk). Questo sommario del rapporto dell’ERG è stato redatto dopo l’esame della documentazione da parte dell’AC. Questo sommario non è stato sottoposto a peer-reviewers esterni da parte di PharmacoEconomics.
Il Professor Luke Vale, Health Economics Research Unit and Health Services Research Unit dell’Università di Aberdeen, ha avuto la funzione di garante e ha fornito consigli e commenti sul lavoro nel corso di tutto il progetto. Il Dott. Mark Crowther, Department of Haematology at Aberdeen Royal Infirmary, ha fornito l’indirizzo clinico e Ms Cynthia Fraser (Documentalista), Health Services Research Unit dell’Università di Aberdeen, ha condotto le ricerche della letteratura e commentato le bozze del rapporto alla HTA.
Altri riconoscimenti e contributi sono riportati in dettaglio nel rapporto dell’ERG .
Le vedute e le opinioni espresse sono quelle degli autori e non riflettono necessariamente quelle del NICE o del Dipartimento della Sanità.
Dwayne Boyers ha completato uno stage (soggiorno di 3 mesi a Dublino, Irlanda) con GlaxoSmithKline come parte di un Master in scienze economiche presso la National University di Irele (NUI), Galway, durante il quale ha completato una tesina sulle modalità di fornitura e rimborso dei farmaci in Irlanda. Come parte del programma tra NUI Galway e GlaxoSmithKline, ha ricevuto un piccolo stipendio per coprire le spese di vitto e alloggio durante il soggiorno a Dublino nel 2009. Gli altri autori non hanno conflitti di interesse da dichiarare.
- 1.National Institute for Health and Clinical Excellence. Guide to the single technology appraisal process. London: NICE. 2009. Available from: http://www.nice.org.uk/media/42D/B3/STAGuideLrFinal.pdf [Accessed 2011 Jan 10].
- 15.National Institute for Health and Clinical Excellence. Thrombocytopenic purpura: eltrombopag. London: NICE. 2010. Available from: http://guidance.nice.org.uk/TA/Wave17/14 [Accessed 2011 Jan 10].
- 17.George JN, El-Harake MA, Aster RH. Thrombocytopenia due to enhanced platelet destruction by immunologic mechanisms. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Williams hematology. New York: McGraw-Hill; 1995. pp. 1315–55. Google Scholar
- 21.GlaxoSmithKline Inc. Product monograph: RevoladeTM eltrombopag tablets 25 mg and 50 mg eltrombopag (as eltrombopag olamine), thrombopoietin receptor agonist. Mississauga (ON): GSK, 2011. Available from: http://www.gsk.ca/english/docs-pdf/Revolade_2011.pdf. [Accessed 2012 Jan 19].
- 24.Chen S, Pi D, Ansari M, et al. Polyclonal intravenous immunologlobulin in patients with immune thrombocytopenic purpura: clinical systematic review [report no. 108]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2008. Available from: http://www.cadth.ca/index.php/en/publication/809 [Accessed 2011 Jan 10].
- 27.Bruneneberg D, Joore MA, Boonen A, et al. Comparing SF-6D and EQ-5D: data from 4 patient populations [abstract]. 6th World Congress on Health Economics; 2007 Jul 8–11; Copenhagen. Available from: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=992656 [Accessed 2011 Jan 10].
- 28.Seymour J, McNamme P, Scott A, et al. Shedding new light onto the ceiling and floor? A quantile regression approach to compare EQ-5D and SF-6D responses. Health Econ. 2009;19:683–96. Google Scholar
- 29.National Institute for Health and Clinical Excellence. Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura [guidance no. 221]. London: NICE. Available from: http://www.nice.org.uk/nicemedia/live/13467/54219/54219.pdf [Accessed 2011 Oct 10]
- 30.Boyers D, Jia X, Crowther M, et al. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP): a single technology appraisal. 2009. Available from: http://www.nice.org.Dec.uk/nicemedia/live/12025/49132/49132.pdf [Accessed 2012 Jan 19].